Alisertib

Puma Biotechnology reports $56.1M net NERLYNX revenue in Q3'24, a ~9% increase from Q3'23 and ~26% from Q2'24. 2,723 ex-factory bottles sold, a ~5% decline from Q3'23 but an ~8% increase from Q2'24. ~65% of patients started at a reduced dose. Forward-looking statements involve risks, including COVID-19 impact and regulatory filings.

Puma Biotechnology reports Q3 2024 net product revenue of $56.1 million, up from $51.6 million in 2023. Total revenue increased to $80.5 million, with net income at $20.3 million. The company focuses on clinical development of alisertib and expects Q4 net product revenue between $46 million and $48 million, revising full-year forecast to $187 million to $190 million.

Puma Biotechnology granted a non-executive employee 5,625 restricted stock units, vesting over three years under the 2017 Employment Inducement Incentive Award Plan.

Puma Biotechnology granted a 5,625-share restricted stock unit award to a new non-executive employee on Nov 4, 2024, under its 2017 Employment Inducement Incentive Award Plan, vesting over three years.

Puma Biotechnology will host a conference call on Nov 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST following Q3 2024 financial results release. The call will be accessible via phone or webcast on their website, with a replay available for 90 days.